echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Express|To make tumor cells "nowhere to escape", Takeda announces the acquisition of γδT cell therapy platform

    Express|To make tumor cells "nowhere to escape", Takeda announces the acquisition of γδT cell therapy platform

    • Last Update: 2021-11-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 27, 2021, Takeda announced the exercise of its option to acquire GammaDelta Therapeutics
    .
    GammaDelta's γδ T cell therapy platform will be obtained, including an allogeneic cell immunotherapy project based on blood and tissue-derived γδ T cell subgroup Vδ1+ cells


    .


    γδT lymphocytes, αβT lymphocytes and B lymphocytes together form the key "guard" of the adaptive immune system
    .
    These cells can recognize dysregulated molecular patterns in stress, pathogen infection, or cancerous cells, and respond quickly to maintain homeostasis


    .


    Vδ1+T cells belong to a subgroup of γδT cells, which are usually found in skin and colon tissues, and there are also lower levels in the blood.


    Compared with Vδ2+T lymphocytes that recognize bacterial phosphoantigens, studies have shown that these cells are acceptable Autologous stem cell transplantation (ASCT) for blood cancer patients provides special benefits in terms of long-term survival


    ▲The advantages of Vδ1+CAR-T cell therapy (picture source: GammaDelta official website)

    GammaDelta isolates Vδ1+T cells from skin and other tissues or blood, and expands them.
    It can continue to further enhance the characteristics of Vδ1+T cells through cell and genetic engineering
    .
    For example, chimeric antigen receptor (CAR) and other transgenes are introduced into Vδ1+ T cells to target cancer and other serious diseases


    .


    "We are committed to developing ready-to-use cell therapies for the benefit of the majority of patients
    .
    " said Dr.


    Christopher Arendt, head of the cell therapy field at Takeda Oncology.


    Reference materials:

    [1] Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors.


    Retrieved October 27, 2021, from https:// -GammaDelta-Therapeutics-to-Accelerate-Development-of-Allogeneic-%CE%B3%CE%B4T-Cell-Therapies-Addressing-Solid-Tumors

    [1] Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors.
    Retrieved October 27, 2021, from https:// -GammaDelta-Therapeutics-to-Accelerate-Development-of-Allogeneic-%CE%B3%CE%B4T-Cell-Therapies-Addressing-Solid-Tumors
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.